

Martin R J Kolb

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9018136/publications.pdf>

Version: 2024-02-01

238
papers

19,493
citations

23879

60
h-index

14012

133
g-index

244
all docs

244
docs citations

244
times ranked

17110
citing authors

#	ARTICLE	IF	CITATIONS
1	Travel Distance to Subspecialty Clinic and Outcomes in Patients with Fibrotic Interstitial Lung Disease. <i>Annals of the American Thoracic Society</i> , 2022, 19, 20-27.	1.5	16
2	R-scale for pulmonary fibrosis: a simple, visual tool for the assessment of health-related quality of life. <i>European Respiratory Journal</i> , 2022, 59, 2100917.	3.1	9
3	Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial. <i>European Respiratory Journal</i> , 2022, 59, 2004538.	3.1	47
4	The Extracellular Matrix-Cell Interaction in ILD. , 2022, , 126-134.		2
5	Neighborhood-Level Disadvantage Impacts on Patients with Fibrotic Interstitial Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 459-467.	2.5	25
6	Association of BMI and Change in Weight With Mortality in Patients With Fibrotic Interstitial Lung Disease. <i>Chest</i> , 2022, 161, 1320-1329.	0.4	25
7	Connective-Tissue Growth Factor Contributes to TGF- β 1-induced Lung Fibrosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2022, 66, 260-270.	1.4	45
8	Impact of Concomitant Medication Burden on Tolerability of Disease-targeted Therapy and Survival in Interstitial Lung Disease. <i>Annals of the American Thoracic Society</i> , 2022, 19, 962-970.	1.5	5
9	Effect of continued antifibrotic therapy after forced vital capacity decline in patients with idiopathic pulmonary fibrosis; a real world multicenter cohort study. <i>Respiratory Medicine</i> , 2022, 191, 106722.	1.3	3
10	The evolution of the <i>European Respiratory Journal</i> : adapting in an era of change. <i>European Respiratory Journal</i> , 2022, 59, 2200037.	3.1	1
11	Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans. <i>JCI Insight</i> , 2022, 7, .	2.3	46
12	Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial). <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 1084-1092.	2.5	10
13	B Cells Are Not Involved in the Regulation of Adenoviral TGF- β 1 or Bleomycin-Induced Lung Fibrosis in Mice. <i>Journal of Immunology</i> , 2022, 208, 1259-1271.	0.4	6
14	Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 247-259.	2.5	15
15	Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. <i>European Respiratory Journal</i> , 2022, 60, 2102571.	3.1	57
16	Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis. <i>Respiratory Research</i> , 2022, 23, 54.	1.4	20
17	Association of BMI with pulmonary function, functional capacity, symptoms, and quality of life in ILD. <i>Respiratory Medicine</i> , 2022, 195, 106792.	1.3	5
18	Prescribing Patterns and Tolerability of Mycophenolate and Azathioprine in Patients with Nonidiopathic Pulmonary Fibrosis Fibrotic Interstitial Lung Disease. <i>Annals of the American Thoracic Society</i> , 2022, 19, 863-867.	1.5	2

#	ARTICLE	IF	CITATIONS
19	Inhalational exposures in patients with fibrotic interstitial lung disease: Presentation, pulmonary function and survival in the <scp>Canadian Registry</scp> for <scp>Pulmonary Fibrosis</scp>. <i>Respirology</i> , 2022, 27, 635-644.	1.3	12
20	FGF19 is Downregulated in Idiopathic Pulmonary Fibrosis and Inhibits Lung Fibrosis in Mice. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2022, , .	1.4	10
21	The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD. <i>Advances in Therapy</i> , 2022, 39, 3881-3895.	1.3	15
22	HSP47: a potential target for fibrotic diseases and implications for therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 49-62.	1.5	30
23	Role of the COX2-PGE ₂ axis in <i>S. pneumoniae</i> -induced exacerbation of experimental fibrosis. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 320, L377-L392.	1.3	8
24	The evolution of the <i>European Respiratory Journal</i>: weathering the publishing pandemic. <i>European Respiratory Journal</i> , 2021, 57, 2100084.	3.1	3
25	Treatment Initiation in Patients with Interstitial Lung Disease in Canada. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1661-1668.	1.5	4
26	Mouse Models of Lung Fibrosis. <i>Methods in Molecular Biology</i> , 2021, 2299, 291-321.	0.4	8
27	FK506-Binding Protein 13 Expression Is Upregulated in Interstitial Lung Disease and Correlated with Clinical Severity. A Potentially Protective Role. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2021, 64, 235-246.	1.4	10
28	The case of methotrexate and the lung: Dr Jekyll and Mr Hyde. <i>European Respiratory Journal</i> , 2021, 57, 2100079.	3.1	10
29	Interstitial lung disease. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2021, 5, 93-96.	0.2	0
30	Circulating fibrocytes are not disease-specific prognosticators in idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2021, 58, 2100172.	3.1	6
31	Guideline-directed management of COVID-19: Do's and Don'ts. <i>European Respiratory Journal</i> , 2021, 57, 2100753.	3.1	9
32	Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases. <i>Respiratory Research</i> , 2021, 22, 84.	1.4	33
33	Prevalence and prognostic impact of physical frailty in interstitial lung disease: A prospective cohort study. <i>Respirology</i> , 2021, 26, 683-689.	1.3	17
34	Fibrotic extracellular matrix induces release of extracellular vesicles with pro-fibrotic miRNA from fibrocytes. <i>Thorax</i> , 2021, 76, 895-906.	2.7	10
35	Systemic Sclerosis and Associated Interstitial Lung Disease in Ontario, Canada: An Examination of Prevalence and Survival Over 10 Years. <i>Journal of Rheumatology</i> , 2021, 48, 1427-1434.	1.0	4
36	Repeat bronchoalveolar lavage in idiopathic pulmonary fibrosis: proceed with caution?. <i>European Respiratory Journal</i> , 2021, 57, 2100691.	3.1	1

#	ARTICLE	IF	CITATIONS
37	A Robust Protocol for Decellularized Human Lung Bioink Generation Amenable to 2D and 3D Lung Cell Culture. <i>Cells</i> , 2021, 10, 1538.	1.8	22
38	Abrogation of mesenchyme-specific TGF- β ² signaling results in lung malformation with prenatal pulmonary cysts in mice. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 320, L1158-L1168.	1.3	9
39	Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease. <i>Respiratory Research</i> , 2021, 22, 202.	1.4	5
40	Extracellular Heat Shock Proteins as Therapeutic Targets and Biomarkers in Fibrosing Interstitial Lung Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9316.	1.8	11
41	Management of Acute Exacerbation of Idiopathic Pulmonary Fibrosis in Specialised and Non-specialised ILD Centres Around the World. <i>Frontiers in Medicine</i> , 2021, 8, 699644.	1.2	8
42	Emerging therapeutic targets for idiopathic pulmonary fibrosis: preclinical progress and therapeutic implications. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 939-948.	1.5	6
43	Real-world patterns of pirfenidone use and safety in patients with idiopathic pulmonary fibrosis in Canada: Data from INSPIRATION PLUS. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2020, 4, 25-30.	0.2	0
44	Guidance production before evidence generation for critical issues: the example of COVID-19. <i>European Respiratory Review</i> , 2020, 29, 200310.	3.0	5
45	Inflammation and intussusceptive angiogenesis in COVID-19: everything in and out of flow. <i>European Respiratory Journal</i> , 2020, 56, 2003147.	3.1	81
46	EFFECT OF NINTEDANIB IN PATIENTS WITH PROGRESSIVE FIBROSING ILDS AND PRESERVED LUNG FUNCTION AT BASELINE: FURTHER ANALYSES OF THE INBUILD TRIAL. <i>Chest</i> , 2020, 158, A1051-A1052.	0.4	1
47	EFFICACY AND SAFETY OF NINTEDANIB IN US/CANADIAN PATIENTS WITH PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASES: FURTHER ANALYSES OF THE INBUILD TRIAL. <i>Chest</i> , 2020, 158, A2613-A2615.	0.4	0
48	Long-term monitoring of patients with fibrotic interstitial lung disease: A Canadian Thoracic Society Position Statement. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2020, 4, 147-155.	0.2	3
49	Triaging Access to Critical Care Resources in Patients With Chronic Respiratory Diseases in the Event of a Major COVID-19 Surge. <i>Chest</i> , 2020, 158, 2270-2274.	0.4	12
50	Progressive fibrosing interstitial lung disease: treatable traits and therapeutic strategies. <i>Current Opinion in Pulmonary Medicine</i> , 2020, 26, 436-442.	1.2	18
51	Position statement from the Canadian Thoracic Society (CTS) on clinical triage thresholds in respiratory disease patients in the event of a major surge during the COVID-19 pandemic. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2020, 4, 214-225.	0.2	3
52	Optimizing care for patients with interstitial lung disease during the COVID-19 pandemic. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2020, 4, 226-228.	0.2	2
53	A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease. <i>Respiratory Research</i> , 2020, 21, 322.	1.4	18
54	Current models of pulmonary fibrosis for future drug discovery efforts. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 931-941.	2.5	31

#	ARTICLE	IF	CITATIONS
55	The evolution of the European Respiratory Journal: ready for the new decade!. European Respiratory Journal, 2020, 55, 1902503.	3.1	0
56	TRIM33 prevents pulmonary fibrosis by impairing TGF- β 1 signalling. European Respiratory Journal, 2020, 55, 1901346.	3.1	45
57	Regulatory T Cells Limit Pneumococcus-Induced Exacerbation of Lung Fibrosis in Mice. Journal of Immunology, 2020, 204, 2429-2438.	0.4	18
58	The importance of interventional timing in the bleomycin model of pulmonary fibrosis. European Respiratory Journal, 2020, 55, 1901105.	3.1	82
59	Nintedanib in patients with progressive fibrosing interstitial lung diseasesâ€”subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respiratory Medicine, 2020, 8, 453-460.	5.2	331
60	Sputum quantitative cytometry in patients with interstitial lung disease and chronic cough. Respiratory Medicine, 2020, 170, 106067.	1.3	2
61	Costs of Workplace Productivity Loss in Patients with Connective Tissue Diseaseâ€”associated Interstitial Lung Disease. Annals of the American Thoracic Society, 2020, 17, 1077-1084.	1.5	5
62	Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation. European Respiratory Journal, 2020, 55, 1901760.	3.1	61
63	Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. BMC Pulmonary Medicine, 2020, 20, 3.	0.8	61
64	Clonally selected primitive endothelial cells promote occlusive pulmonary arteriopathy and severe pulmonary hypertension in rats exposed to chronic hypoxia. Scientific Reports, 2020, 10, 1136.	1.6	15
65	Making the case for causality: what role do lung microbiota play in idiopathic pulmonary fibrosis?. European Respiratory Journal, 2020, 55, 2000318.	3.1	5
66	Practical Considerations for the Diagnosis and Treatment of Fibrotic Interstitial Lung Disease During the Coronavirus Disease 2019 Pandemic. Chest, 2020, 158, 1069-1078.	0.4	57
67	Prognostic impact of typical and probable usual interstitial pneumonia pattern in idiopathic pulmonary fibrosis: is the debate about biopsy a <i>Star Wars</i> saga?. European Respiratory Journal, 2020, 55, 2000590.	3.1	2
68	Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE). American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1505-1512.	2.5	50
69	Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. European Respiratory Journal, 2019, 54, 1900161.	3.1	164
70	Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1146-1153.	2.5	60
71	Fibrocytes and fibroblastsâ€”Where are we now. International Journal of Biochemistry and Cell Biology, 2019, 116, 105595.	1.2	46
72	The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease. Advances in Therapy, 2019, 36, 3279-3287.	1.3	45

#	ARTICLE	IF	CITATIONS
73	Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. <i>New England Journal of Medicine</i> , 2019, 381, 1718-1727.	13.9	1,338
74	Surfactant dysfunction and alveolar collapse are linked with fibrotic septal wall remodeling in the TGF- β 1-induced mouse model of pulmonary fibrosis. <i>Laboratory Investigation</i> , 2019, 99, 830-852.	1.7	30
75	Costs of Workplace Productivity Loss in Patients With Fibrotic Interstitial Lung Disease. <i>Chest</i> , 2019, 156, 887-895.	0.4	14
76	A genome-wide association study implicates <i>NR2F2</i> in lymphangioliomyomatosis pathogenesis. <i>European Respiratory Journal</i> , 2019, 53, 1900329.	3.1	14
77	Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage. <i>ERJ Open Research</i> , 2019, 5, 00127-2018.	1.1	21
78	The Role of Follow-up Evaluation in the Diagnostic Algorithm of Idiopathic Interstitial Pneumonia: A Retrospective Study. <i>Scientific Reports</i> , 2019, 9, 6452.	1.6	7
79	Pulmonary fibrosis: 'idiopathic' is not 'cryptogenic'. <i>European Respiratory Journal</i> , 2019, 53, 1900400.	3.1	1
80	The natural history of progressive fibrosing interstitial lung diseases. <i>Respiratory Research</i> , 2019, 20, 57.	1.4	151
81	Idiopathic interstitial pneumonia or idiopathic interstitial pneumonitis: what's in a name?. <i>European Respiratory Journal</i> , 2019, 53, 1801939.	3.1	6
82	The Role of Infection in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. <i>Mediators of Inflammation</i> , 2019, 2019, 1-10.	1.4	38
83	Mechanical stress-induced mast cell degranulation activates TGF- β 1 signalling pathway in pulmonary fibrosis. <i>Thorax</i> , 2019, 74, 455-465.	2.7	63
84	Molecular breath analysis for IPF: Can we make a few breaths count?. <i>Respirology</i> , 2019, 24, 404-405.	1.3	2
85	What have we learned from basic science studies on idiopathic pulmonary fibrosis?. <i>European Respiratory Review</i> , 2019, 28, 190029.	3.0	42
86	A cross-sectional evaluation of the idiopathic pulmonary fibrosis patient satisfaction and quality of life with a care coordinator. <i>Journal of Thoracic Disease</i> , 2019, 11, 5547-5556.	0.6	7
87	Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials. <i>European Respiratory Journal</i> , 2019, 54, 1801797.	3.1	28
88	Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of <i>Respiratory</i> , <i>Sleep</i> , and <i>Critical Care Journals</i> . <i>Annals of the American Thoracic Society</i> , 2019, 16, 22-28.	1.5	458
89	Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2019, 53, 1800663.	3.1	73
90	The Role of Mast Cells in the Pathophysiology of Pulmonary Fibrosis. <i>Molecular and Translational Medicine</i> , 2019, , 135-173.	0.4	0

#	ARTICLE	IF	CITATIONS
91	Therapeutic effects of nintedanib are not influenced by emphysema in the INPULSIS trials. <i>European Respiratory Journal</i> , 2019, 53, 1801655.	3.1	22
92	Therapeutic targets and early stage clinical trials for pulmonary fibrosis. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 19-28.	1.9	16
93	IL-6 mediates ER expansion during hyperpolarization of alternatively activated macrophages. <i>Immunology and Cell Biology</i> , 2019, 97, 203-217.	1.0	18
94	Changes in biomarkers in patients with idiopathic pulmonary fibrosis (IPF) treated with nintedanib and sildenafil. , 2019, , .		3
95	Thoracoscopic surgery for tracheal and carinal resection and reconstruction under spontaneous ventilation. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 2746-2754.	0.4	54
96	Idiopathic pulmonary fibrosis: idiopathic no more?. <i>Lancet Respiratory Medicine</i> , 2018, 6, 84-85.	5.2	8
97	Turning thirty: evolution but not revolution at the ER. <i>European Respiratory Journal</i> , 2018, 51, 1702594.	3.1	0
98	Synergistic role of HSP90 α and HSP90 β to promote myofibroblast persistence in lung fibrosis. <i>European Respiratory Journal</i> , 2018, 51, 1700386.	3.1	41
99	Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis. <i>Respiration</i> , 2018, 95, 317-326.	1.2	42
100	The increasing mortality of idiopathic pulmonary fibrosis: fact or fallacy?. <i>European Respiratory Journal</i> , 2018, 51, 1702420.	3.1	33
101	A Switch in TGF- β Signaling Explains Contradictory Findings in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 157-159.	2.5	3
102	Adenoviral vector-mediated GM-CSF gene transfer improves anti-mycobacterial immunity in mice – role of regulatory T cells. <i>Immunobiology</i> , 2018, 223, 331-341.	0.8	3
103	Lysyl Oxidase–Like 1 Protein Deficiency Protects Mice from Adenoviral Transforming Growth Factor- β -induced Pulmonary Fibrosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2018, 58, 461-470.	1.4	44
104	Acute exacerbations of progressive-fibrosing interstitial lung diseases. <i>European Respiratory Review</i> , 2018, 27, 180071.	3.0	109
105	Comprehensive management of fibrotic interstitial lung diseases: A Canadian Thoracic Society position statement. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2018, 2, 234-243.	0.2	8
106	Transbronchial lung cryobiopsy for ILD: Ready or not, here it comes?. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2018, 2, 257-258.	0.2	0
107	Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. <i>New England Journal of Medicine</i> , 2018, 379, 1722-1731.	13.9	207
108	Clinical and economic burden of idiopathic pulmonary fibrosis in Quebec, Canada. <i>ClinicoEconomics and Outcomes Research</i> , 2018, Volume 10, 127-137.	0.7	16

#	ARTICLE	IF	CITATIONS
109	Optimising experimental research in respiratory diseases: an ERS statement. <i>European Respiratory Journal</i> , 2018, 51, 1702133.	3.1	98
110	What's in a name? That which we call IPF, by any other name would act the same. <i>European Respiratory Journal</i> , 2018, 51, 1800692.	3.1	226
111	Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2018, 52, 1702593.	3.1	29
112	Nanoscale dysregulation of collagen structure-function disrupts mechano-homeostasis and mediates pulmonary fibrosis. <i>ELife</i> , 2018, 7, .	2.8	99
113	Matrix abnormalities in pulmonary fibrosis. <i>European Respiratory Review</i> , 2018, 27, 180033.	3.0	165
114	Macitentan reduces progression of TGF- β 21-induced pulmonary fibrosis and pulmonary hypertension. <i>European Respiratory Journal</i> , 2018, 52, 1701857.	3.1	46
115	Radiological diagnosis of interstitial lung disease: is it all about pattern recognition?. <i>European Respiratory Journal</i> , 2018, 52, 1801321.	3.1	4
116	Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. <i>Thorax</i> , 2017, 72, 340-346.	2.7	191
117	Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis. <i>Thorax</i> , 2017, 72, 148-153.	2.7	66
118	Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone. <i>Respiration</i> , 2017, 93, 415-423.	1.2	63
119	An Official American Thoracic Society Workshop Report: Use of Animal Models for the Preclinical Assessment of Potential Therapies for Pulmonary Fibrosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2017, 56, 667-679.	1.4	267
120	Acute exacerbations of idiopathic pulmonary fibrosis: tough to define; tougher to manage. <i>European Respiratory Journal</i> , 2017, 49, 1700811.	3.1	8
121	Palliative care in interstitial lung disease: living well. <i>Lancet Respiratory Medicine</i> , the, 2017, 5, 968-980.	5.2	185
122	Overexpression of OSM and IL-6 impacts the polarization of pro-fibrotic macrophages and the development of bleomycin-induced lung fibrosis. <i>Scientific Reports</i> , 2017, 7, 13281.	1.6	73
123	Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study. <i>European Respiratory Journal</i> , 2017, 50, 1700936.	3.1	75
124	Personalised medicine for IPF: getting closer, but not there yet. <i>Lancet Respiratory Medicine</i> , the, 2017, 5, 836-837.	5.2	2
125	Therapeutic targets in idiopathic pulmonary fibrosis. <i>Respiratory Medicine</i> , 2017, 131, 49-57.	1.3	92
126	An Official American Thoracic Society Workshop Report: Translational Research in Rare Respiratory Diseases. <i>Annals of the American Thoracic Society</i> , 2017, 14, 1239-1247.	1.5	4

#	ARTICLE	IF	CITATIONS
127	Supplemental Oxygen in Interstitial Lung Disease: An Art in Need of Science. <i>Annals of the American Thoracic Society</i> , 2017, 14, 1373-1377.	1.5	30
128	M2-polarized and tumor-associated macrophages alter NK cell phenotype and function in a contact-dependent manner. <i>Journal of Leukocyte Biology</i> , 2017, 101, 285-295.	1.5	72
129	Evaluation of patients with fibrotic interstitial lung disease: A Canadian Thoracic Society position statement. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2017, 1, 133-141.	0.2	15
130	A female patient with recurrent lung lesion and hilar lymphadenopathy. <i>Journal of Thoracic Disease</i> , 2017, 9, 1858-1863.	0.6	0
131	A 43-year-old man with cough, expectoration and recurrent wheezing. <i>Journal of Thoracic Disease</i> , 2016, 8, 3468-3477.	0.6	0
132	The Canadian Registry for Pulmonary Fibrosis: Design and Rationale of a National Pulmonary Fibrosis Registry. <i>Canadian Respiratory Journal</i> , 2016, 2016, 1-7.	0.8	45
133	Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis. <i>PLoS ONE</i> , 2016, 11, e0151425.	1.1	223
134	Amplification of TGF β 2 Induced ITGB6 Gene Transcription May Promote Pulmonary Fibrosis. <i>PLoS ONE</i> , 2016, 11, e0158047.	1.1	34
135	First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of $\geq 50\%$ of Predicted Value. <i>Lung</i> , 2016, 194, 739-743.	1.4	102
136	Pathways to Precision Medicine in Idiopathic Pulmonary Fibrosis. Time to Relax?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 1315-1317.	2.5	4
137	Study the past to divine the future. Confucius' wisdom doesn't work for idiopathic pulmonary fibrosis. <i>Thorax</i> , 2016, 71, 399-400.	2.7	2
138	Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis: methodological concerns. <i>European Respiratory Journal</i> , 2016, 48, 1524-1526.	3.1	16
139	Nintedanib Reduces Disease Progression in Patients With Idiopathic Pulmonary Fibrosis Irrespective of GAP Stage at Baseline in the INPULSIS Trials. <i>Chest</i> , 2016, 150, 540A.	0.4	0
140	Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. <i>Lancet Respiratory Medicine</i> , 2016, 4, 381-389.	5.2	189
141	Human mesenchymal stem cells attenuate early damage in a ventilated pig model of acute lung injury. <i>Stem Cell Research</i> , 2016, 17, 25-31.	0.3	29
142	An American Thoracic Society Official Research Statement: Future Directions in Lung Fibrosis Research. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 193, 792-800.	2.5	22
143	Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2016, 47, 1776-1784.	3.1	61
144	Fibroblast growth factor-1 attenuates TGF β 1-induced lung fibrosis. <i>Journal of Pathology</i> , 2016, 240, 197-210.	2.1	81

#	ARTICLE	IF	CITATIONS
145	Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada. <i>European Respiratory Journal</i> , 2016, 48, 187-195.	3.1	130
146	Anti-acid treatment in patients with IPF: interpret results from post-hoc, subgroup, and exploratory analyses with great caution – Authors' reply. <i>Lancet Respiratory Medicine</i> , 2016, 4, e48.	5.2	6
147	Abnormal extracellular matrix: The common thread of diseases progression in fibrosis?. <i>Arthritis and Rheumatology</i> , 2016, 68, n/a-n/a.	2.9	4
148	Surfactant dysfunction during overexpression of TGF- β 1 precedes profibrotic lung remodeling in vivo. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2016, 310, L1260-L1271.	1.3	49
149	Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 265-275.	2.5	1,006
150	High Oxygen Delivery to Preserve Exercise Capacity in Patients with Idiopathic Pulmonary Fibrosis Treated with Nintedanib. Methodology of the HOPE-IPF Study. <i>Annals of the American Thoracic Society</i> , 2016, 13, 1640-1647.	1.5	37
151	Stretch-induced Activation of Transforming Growth Factor- β 1 in Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 84-96.	2.5	165
152	Mucking around in the Genome: MUC5B in Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 193, 355-357.	2.5	4
153	Interstitial lung disease: time to rethink the snapshot diagnosis?. <i>Thorax</i> , 2016, 71, 5-7.	2.7	1
154	Idiopathische Lungenfibrose. , 2016, , 127-141.		0
155	Molecular classification of idiopathic pulmonary fibrosis: Personalized medicine, genetics and biomarkers. <i>Respirology</i> , 2015, 20, 1010-1022.	1.3	44
156	Why do patients get idiopathic pulmonary fibrosis? Current concepts in the pathogenesis of pulmonary fibrosis. <i>BMC Medicine</i> , 2015, 13, 176.	2.3	38
157	A novel profibrotic mechanism mediated by TGF- β 2-stimulated collagen prolyl hydroxylase expression in fibrotic lung mesenchymal cells. <i>Journal of Pathology</i> , 2015, 236, 384-394.	2.1	40
158	Disruption of Calcium Signaling in Fibroblasts and Attenuation of Bleomycin-Induced Fibrosis by Nifedipine. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2015, 53, 450-458.	1.4	42
159	Antifibrotic Role of β -Crystallin Inhibition in Pleural and Subpleural Fibrosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2015, 52, 244-252.	1.4	19
160	<i>Streptococcus pneumoniae</i> triggers progression of pulmonary fibrosis through pneumolysin. <i>Thorax</i> , 2015, 70, 636-646.	2.7	71
161	A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials. <i>European Respiratory Journal</i> , 2015, 46, 243-249.	3.1	48
162	Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2015, 45, 1434-1445.	3.1	667

#	ARTICLE	IF	CITATIONS
163	Drug development for chronic lung disease –Mission impossible?. <i>Respirology</i> , 2015, 20, 13-14.	1.3	4
164	Biomarkers in interstitial lung disease: moving towards composite indexes and multimarkers?. <i>Current Pulmonology Reports</i> , 2015, 4, 125-129.	0.5	0
165	Rapid detection of circulating fibrocytes by flowcytometry in idiopathic pulmonary fibrosis. <i>Annals of Thoracic Medicine</i> , 2015, 10, 279-83.	0.7	8
166	Pulmonary and Cardiac Function in Asymptomatic Obese Subjects and Changes following a Structured Weight Reduction Program: A Prospective Observational Study. <i>PLoS ONE</i> , 2014, 9, e107480.	1.1	12
167	Cardiopulmonary Exercise Testing to Detect Chronic Thromboembolic Pulmonary Hypertension in Patients with Normal Echocardiography. <i>Respiration</i> , 2014, 87, 379-387.	1.2	89
168	Staging of idiopathic pulmonary fibrosis: past, present and future. <i>European Respiratory Review</i> , 2014, 23, 220-224.	3.0	69
169	Fibrocytes and Progression of Fibrotic Lung Disease. Ready for Showtime?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 1338-1339.	2.5	12
170	Influenza Promotes Collagen Deposition via $\alpha 6$ Integrin-mediated Transforming Growth Factor $\beta 2$ Activation. <i>Journal of Biological Chemistry</i> , 2014, 289, 35246-35263.	1.6	48
171	Design of the INPULSIS [®] trials: Two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. <i>Respiratory Medicine</i> , 2014, 108, 1023-1030.	1.3	82
172	The small heat shock protein α -crystallin is essential for the nuclear localization of Smad4: impact on pulmonary fibrosis. <i>Journal of Pathology</i> , 2014, 232, 458-472.	2.1	52
173	Glycosyltransferases and Glycosaminoglycans in Bleomycin and Transforming Growth Factor $\beta 2$ -Induced Pulmonary Fibrosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2014, 50, 583-594.	1.4	22
174	Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. <i>New England Journal of Medicine</i> , 2014, 370, 2071-2082.	13.9	3,351
175	miR-92a regulates TGF $\beta 1$ -induced WISP1 expression in pulmonary fibrosis. <i>International Journal of Biochemistry and Cell Biology</i> , 2014, 53, 432-441.	1.2	95
176	Platelet derived growth factor-evoked Ca ²⁺ wave and matrix gene expression through phospholipase C in human pulmonary fibroblast. <i>International Journal of Biochemistry and Cell Biology</i> , 2013, 45, 1516-1524.	1.2	29
177	New treatment and markers of prognosis for idiopathic pulmonary fibrosis: lessons learned from translational research. <i>Expert Review of Respiratory Medicine</i> , 2013, 7, 465-478.	1.0	14
178	Idiopathic Pulmonary Fibrosis: From Epithelial Injury to Biomarkers - Insights from the Bench Side. <i>Respiration</i> , 2013, 86, 441-452.	1.2	108
179	Extracellular matrix microenvironment contributes actively to pulmonary fibrosis. <i>Current Opinion in Pulmonary Medicine</i> , 2013, 19, 446-452.	1.2	48
180	Vascular Repair and Regeneration as a Therapeutic Target for Pulmonary Arterial Hypertension. <i>Respiration</i> , 2013, 85, 355-364.	1.2	16

#	ARTICLE	IF	CITATIONS
181	Fibrocytes in pulmonary fibrosis: a brief synopsis. <i>European Respiratory Review</i> , 2013, 22, 552-557.	3.0	52
182	Inhibition of HSP27 blocks fibrosis development and EMT features by promoting Snail degradation. <i>FASEB Journal</i> , 2013, 27, 1549-1560.	0.2	95
183	Lung surgery in interstitial lung disease-a safe and useful procedure?. <i>Journal of Thoracic Disease</i> , 2013, 5, 375-7.	0.6	5
184	Transforming Growth Factor- β 2 Evokes Ca^{2+} Waves and Enhances Gene Expression in Human Pulmonary Fibroblasts. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2012, 46, 757-764.	1.4	66
185	Angiogenesis in Pulmonary Fibrosis. <i>Chest</i> , 2012, 142, 200-207.	0.4	98
186	Identification of RARRES1 as a core regulator in liver fibrosis. <i>Journal of Molecular Medicine</i> , 2012, 90, 1439-1447.	1.7	10
187	Fibrocytes in chronic lung disease – Facts and controversies. <i>Pulmonary Pharmacology and Therapeutics</i> , 2012, 25, 263-267.	1.1	17
188	Adenovirus-Mediated Gene Transfer of TGF- β 1 to the Renal Glomeruli Leads to Proteinuria. <i>American Journal of Pathology</i> , 2012, 180, 940-951.	1.9	20
189	Oxidative stress contributes to the induction and persistence of TGF- β 1 induced pulmonary fibrosis. <i>International Journal of Biochemistry and Cell Biology</i> , 2011, 43, 1122-1133.	1.2	71
190	Clinical trials in idiopathic pulmonary fibrosis: update and perspectives. <i>Clinical Investigation</i> , 2011, 1, 1669-1680.	0.0	1
191	Transient Overexpression of Gremlin Results in Epithelial Activation and Reversible Fibrosis in Rat Lungs. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2011, 44, 870-878.	1.4	60
192	Pulmonary Hypertension and Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2011, 45, 1-15.	1.4	199
193	Viruses and Acute Exacerbations of Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 1583-1584.	2.5	9
194	Pulmonary Microcirculation in Interstitial Lung Disease. <i>Proceedings of the American Thoracic Society</i> , 2011, 8, 516-521.	3.5	34
195	Local Delivery of GM-CSF Protects Mice from Lethal Pneumococcal Pneumonia. <i>Journal of Immunology</i> , 2011, 187, 5346-5356.	0.4	72
196	<i>In Vivo</i> Role of Platelet-Derived Growth Factor- β in Airway Smooth Muscle Proliferation in Mouse Lung. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2011, 45, 566-572.	1.4	49
197	Fibrocytes in Interstitial Lung Disease. , 2011, , 131-141.		0
198	Have advanced research technologies made real impact on respiratory medicine?. <i>Respirology</i> , 2010, 15, 876-880.	1.3	6

#	ARTICLE	IF	CITATIONS
199	Smad3-dependent and -independent pathways are involved in peritoneal membrane injury. <i>Kidney International</i> , 2010, 77, 319-328.	2.6	87
200	Intedanib, a triple kinase inhibitor of VEGFR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis. <i>IDrugs: the Investigational Drugs Journal</i> , 2010, 13, 332-45.	0.7	13
201	Circulating Fibrocytes Are an Indicator of Poor Prognosis in Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 588-594.	2.5	486
202	Update on models of pulmonary fibrosis therapy for preclinical drug research. <i>Expert Opinion on Drug Discovery</i> , 2009, 4, 939-946.	2.5	7
203	Identification of Fibrocytes in Peripheral Blood. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 1279-1280.	2.5	3
204	<i>Respirology</i> year in review 2008: Basic science. <i>Respirology</i> , 2009, 14, 318-326.	1.3	0
205	How useful is traditional herbal medicine for pulmonary fibrosis?. <i>Respirology</i> , 2009, 14, 1082-1091.	1.3	20
206	Treating IPF "all or nothing? A PRO vs CON debate. <i>Respirology</i> , 2009, 14, 1072-1081.	1.3	9
207	ATP stimulates Ca ²⁺ -waves and gene expression in cultured human pulmonary fibroblasts. <i>International Journal of Biochemistry and Cell Biology</i> , 2009, 41, 2477-2484.	1.2	29
208	Essential Role of Osteopontin in Smoking-Related Interstitial Lung Diseases. <i>American Journal of Pathology</i> , 2009, 174, 1683-1691.	1.9	59
209	VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats. <i>Journal of Clinical Investigation</i> , 2009, 119, 1298-1311.	3.9	184
210	Comparison between conventional and "clinical" assessment of experimental lung fibrosis. <i>Journal of Translational Medicine</i> , 2008, 6, 16.	1.8	59
211	Targeting fibrosis in respiratory lung disease. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2008, 5, 97-100.	0.5	0
212	The use of small animal imaging in respiratory disease drug discovery. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2008, 5, 81-85.	0.5	0
213	The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis?. <i>International Journal of Biochemistry and Cell Biology</i> , 2008, 40, 362-382.	1.2	781
214	Progressive pulmonary fibrosis is mediated by TGF- β 1 isoform 1 but not TGF- β 3. <i>International Journal of Biochemistry and Cell Biology</i> , 2008, 40, 484-495.	1.2	148
215	Animal models of pulmonary fibrosis: how far from effective reality?. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2008, 294, L151-L151.	1.3	33
216	TGF- β 1 Induces Progressive Pleural Scarring and Subpleural Fibrosis. <i>Journal of Immunology</i> , 2007, 179, 6043-6051.	0.4	114

#	ARTICLE	IF	CITATIONS
217	TGF β 2 and Smad3 link inflammation to progressive fibrosis. International Congress Series, 2007, 1302, 103-113.	0.2	0
218	The transforming growth factor-beta (TGF β 2) family and pulmonary fibrosis. Drug Discovery Today Disease Mechanisms, 2006, 3, 99-103.	0.8	13
219	Models of pulmonary fibrosis. Drug Discovery Today: Disease Models, 2006, 3, 243-249.	1.2	24
220	Strategies targeting fibrosis in pulmonary disease. Drug Discovery Today: Therapeutic Strategies, 2006, 3, 389-394.	0.5	3
221	Gene Therapy for Pulmonary Diseases. Chest, 2006, 130, 879-884.	0.4	53
222	Transforming Growth Factor β 2: Importance in Long-Term Peritoneal Membrane Changes. Peritoneal Dialysis International, 2005, 25, 15-17.	1.1	32
223	TGF β 2 and Smad3 Signaling Link Inflammation to Chronic Fibrogenesis. Journal of Immunology, 2005, 175, 5390-5395.	0.4	227
224	Transforming Growth Factor β 2; Peptide Signaling in Lung Development: Bronchopulmonary Dysplasia, Lung Fibrosis and Emphysema. Current Respiratory Medicine Reviews, 2005, 1, 325-329.	0.1	0
225	Progressive Transforming Growth Factor β 2-induced Lung Fibrosis Is Blocked by an Orally Active ALK5 Kinase Inhibitor. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 889-898.	2.5	237
226	Connective Tissue Growth Factor Is Crucial to Inducing a Profibrotic Environment in α 1-Fibrosis-Resistant Balb/c Mouse Lungs. American Journal of Respiratory Cell and Molecular Biology, 2004, 31, 510-516.	1.4	142
227	Smad3 Null Mice Develop Airspace Enlargement and Are Resistant to TGF β 2-Mediated Pulmonary Fibrosis. Journal of Immunology, 2004, 173, 2099-2108.	0.4	349
228	Transdiaphragmatic liver herniation mimicking pulmonary nodule. European Journal of Radiology Extra, 2003, 46, 17-20.	0.1	2
229	Adenoviral Gene Transfer of Connective Tissue Growth Factor in the Lung Induces Transient Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 770-778.	2.5	121
230	Re-evaluation of Fibrogenic Cytokines in Lung Fibrosis. Current Pharmaceutical Design, 2003, 9, 39-49.	0.9	151
231	Differences in the Fibrogenic Response after Transfer of Active Transforming Growth Factor β 1 Gene to Lungs of α 1-Fibrosis-prone and α 1-Fibrosis-resistant Mouse Strains. American Journal of Respiratory Cell and Molecular Biology, 2002, 27, 141-150.	1.4	161
232	Inflammatory Cytokines, Angiogenesis, and Fibrosis in the Rat Peritoneum. American Journal of Pathology, 2002, 160, 2285-2294.	1.9	123
233	Antiangiogenic and Antifibrotic Gene Therapy in a Chronic Infusion Model of Peritoneal Dialysis in Rats. Journal of the American Society of Nephrology: JASN, 2002, 13, 721-728.	3.0	112
234	Budesonide Enhances Repeated Gene Transfer and Expression in the Lung with Adenoviral Vectors. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 866-872.	2.5	26

#	ARTICLE	IF	CITATIONS
235	Transient Transgene Expression of Decorin in the Lung Reduces the Fibrotic Response to Bleomycin. American Journal of Respiratory and Critical Care Medicine, 2001, 163, 770-777.	2.5	172
236	Transient expression of IL-1 β induces acute lung injury and chronic repair leading to pulmonary fibrosis. Journal of Clinical Investigation, 2001, 107, 1529-1536.	3.9	655
237	Gene Transfer of Transforming Growth Factor- β 1 to the Rat Peritoneum. Journal of the American Society of Nephrology: JASN, 2001, 12, 2029-2039.	3.0	184
238	Clinical relevance of rheumatoid factor and anti-citrullinated peptides in fibrotic interstitial lung disease. Respirology, 0, , .	1.3	4